What Sponsors Actually Weigh When Choosing Research Sites

Site selection decisions get made in rooms your site will never enter. A feasibility questionnaire, a CDA, maybe a 45-minute qualification call, and then a spreadsheet comparison against 30 other candidates. Understanding what actually drives that comparison lets you position your site deliberately instead of hoping the data speaks for itself.

The decision is mostly about risk

Sponsors and CROs are not hunting for the site with the most impressive pitch. They are trying to avoid the outcome that wrecks a study timeline: a site that gets activated, consumes startup budget and monitoring hours, and enrolls one or two participants. Non-enrolling sites are a well-known drag on trial budgets, and the people choosing sites have been burned before.

So every question on a feasibility form is really asking: how likely is this site to produce, and how much will it cost us to manage? Answer that question explicitly and you stand out.

What gets weighted heaviest

Documented performance in the same indication

Prior experience matters less than prior enrollment numbers in a comparable protocol. "We have conducted 14 cardiology trials" is weak. "In our last three HFpEF studies we enrolled 9, 12, and 7 against targets of 8, 10, and 10, with screen-fail rates between 30 and 40 percent" is strong. Keep an indication-level performance log so you can produce those figures in an afternoon.

A defensible patient access story

Sponsors want to know where participants will come from, not that they will exist. Be specific about which channels you actually use and what they yield:

• Internal EHR query counts for the key inclusion criteria
• Referring physician relationships, named by practice and specialty
• Registry or prior-participant database size, with consent-to-recontact status
• Community outreach you genuinely run, not aspirations

Startup speed

Cycle time from site selection to first participant consented is one of the few metrics sponsors track obsessively. If your contract and budget turnaround is fast, or your IRB is central and you have no local committee layer, say so with numbers. Sites that can commit to activation in weeks rather than months get picked.

Staffing depth and turnover

A single coordinator carrying 12 studies is a risk flag. Sponsors look for coverage: who backs up the lead coordinator, how long staff have been in seat, whether the PI has protected research time. Describe your capacity honestly, including how many studies your team currently carries.

Quality signals

Monitoring findings, query resolution time, protocol deviation patterns, and audit history all get reviewed when available. Clean data entered within a week of visit is more persuasive than any narrative.

Practical moves that improve your odds

1. Build a standing site capability packet. Performance by indication, patient population demographics, equipment list, staff CVs and tenure, startup timelines. Update quarterly so feasibility responses take hours, not days.
2. Never guess on feasibility numbers. Run the query. A commitment you miss costs you the next three studies with that sponsor.
3. Decline studies you cannot enroll. Saying no builds more credibility than a low-enrolling yes.
4. Debrief with your CRA after every study closes. Ask what your site looked like from their side, and fix what they name.
5. Stay in front of sponsors between studies. A short annual performance summary to the feasibility contacts you know keeps your site in the consideration set.

Site selection rewards sites that make themselves easy to evaluate. Be the one with the numbers ready.